XCyton Launches New Diagnostic Tool – Syndrome Evaluation System

Science & Technology

Over the next twelve months XCyton plans to expand across all metros in India

(From L-R) Dr Latha Lakshaman, Director and Dr BV Ravi Kumar, Chairman & MD, both of XCyton Diagnostics , Dr Kiran Mazumdar Shaw, Chairman & MD, Biocon, Dr Prem Pavoor, Associate Director FIL Capital Advisor (India) and Dr Ketan Patel, Principal, Fidelity Bio-sciences

XCyton Diagnostics has launched Syndrome Evaluation System (SES) which will result in the effective treatment and saving of lives.

XCyton’s Syndrome Evaluation System (SES) allows for the immediate identification of multiple organisms inclusive of bacteria, viruses, fungi and parasites, in a specific test from a single sample. This process provides the clinician with a fast, definitive assessment of a patient who is presenting a set of symptoms common to multiple pathogens.

Dr BV Ravi Kumar, Founder Chairman and Managing Director of XCyton Diagnostics says, “My belief that lives can be saved and disabilities can be prevented if the diagnosis is made early during the infection led to the creation of SES. It is inhuman not to apply available scientific knowledge to counter oppressive illnesses. In life style diseases, people can take complete control of their health. In case of infections it is not possible. I empathise with that
fact. ”

In one sample, one test, all the probable causative agents that can cause a syndrome can be diagnosed through SES, in a short duration of just seven hours, thus leading to early initiation of appropriate therapy and reduction of death and disability.

Dr Kiran Mazumdar Shaw who heads leading biotechnology enterprise, Biocon, has personally invested in XCyton. She believes that molecular diagnostics is the medical technology of the future and development of SES is a significant milestone in the history of molecular diagnostics.

XCyton is now backed by Fidelity Growth Partners India (FGPI) which is the India focused private equity arm of Fidelity Worldwide Investment.

Features of SES:

  • Fast – Takes seven hours while conventional tests take more than 72 hrs
  • Accurate – Higher detection rates , 4 times more than the conventional tests i.e 15 per cent vs 75 per cent
  • Direct demonstration of the pathogen can be treated straight away
  • Physician can rule out or rule in an infection, as they test for spectrum of bugs at once
  • Cost effective – Reduces multiple tests and reduces ICU stay
  • Specific – All studies showed that it does not detect false positives among various types of controls

EH News Bureau

source: http://www.ExpressHealthcare.in / Home> Market> Article / April 2012

Leave a Reply